22101005|t|The effect of amyloid associated proteins on the expression of genes involved in amyloid-beta clearance by adult human astrocytes.
22101005|a|Astrocytes appear to be important mediators in the clearance of amyloid beta1-42 (Abeta), the key component of senile plaques characteristic of Alzheimer's disease (AD). Recently, we found the amyloid associated proteins (AAPs) alpha1-antichymotrypsin (ACT), apolipoprotein J and E (ApoJ and ApoE) and a mixture of serum amyloid P (SAP) and C1q (SAP-C1q) to modify Abeta-uptake by human astrocytes. Here we investigated the effect of oligomeric (Abetaoligo) and fibrillar Abeta (Abetafib), alone and in combination with a panel of AAPs on the astrocytic expression of genes proposed to be involved in Abeta-uptake and degradation. Primary human astrocytes (isolated from non-demented control (n=4) and AD patient (n=4) brain specimens) were exposed to either Abetaoligo or Abetafib preparations with or without the above mentioned AAPs. Quantitative gene expression analysis of Abeta-receptors Scavenger receptor B1 (SCARB1), macrophage receptor with collagenous structure (MARCO) and low density lipoprotein receptor related protein-2 (LRP2 or megalin) as well as of Abeta-degrading enzymes neprilysin (NEP), insulin-degrading enzyme (IDE) and metalloproteinase-9 (MMP-9) was performed by real-time PCR. Basal expression of NEP, IDE and SCARB1 was easily detected whereas expression of MARCO, LRP2 and MMP-9 could only be detected upon pre-amplification. Basal expression of NEP, IDE and SCARB1 did not change upon exposure to Abetaoligo or Abetafib alone in any of the investigated astrocyte cultures. Interestingly NEP expression was increased upon exposure to ApoE in combination with both Abeta-preparations, and also SCARB1 expression was induced upon treatment with ApoE in combination with Abetafib in astrocytes from non-demented controls. Further, SAP-C1q increased SCARB1 expression in control astrocytes when combined with Abetaoligo. These alterations were not found in astrocytes from AD patients. Thus, we conclude that Abeta alone apparently does not affect the astrocytic expression of IDE, NEP or SCARB1. However, NEP and SCARB1 expression is increased in astrocytes from non-demented subjects when exposed to Abeta combined with AAPs like ApoE. These astrocytic gene expression-regulatory mechanisms appear to be defective in AD and thus might contribute to the development and progression of AD pathology.
22101005	81	93	amyloid-beta	Gene	351
22101005	113	118	human	Species	9606
22101005	213	218	Abeta	Gene	351
22101005	275	294	Alzheimer's disease	Disease	MESH:D000544
22101005	296	298	AD	Disease	MESH:D000544
22101005	359	382	alpha1-antichymotrypsin	Gene	12
22101005	390	412	apolipoprotein J and E	Gene	1191;348
22101005	414	418	ApoJ	Gene	1191
22101005	423	427	ApoE	Gene	348
22101005	463	466	SAP	Gene	325
22101005	472	475	C1q	Gene	712
22101005	477	484	SAP-C1q	Gene	712
22101005	496	501	Abeta	Gene	351
22101005	512	517	human	Species	9606
22101005	603	608	Abeta	Gene	351
22101005	732	737	Abeta	Gene	351
22101005	770	775	human	Species	9606
22101005	833	835	AD	Disease	MESH:D000544
22101005	836	843	patient	Species	9606
22101005	904	912	Abetafib	Chemical	-
22101005	1009	1014	Abeta	Gene	351
22101005	1025	1046	Scavenger receptor B1	Gene	949
22101005	1048	1054	SCARB1	Gene	949
22101005	1057	1103	macrophage receptor with collagenous structure	Gene	8685
22101005	1105	1110	MARCO	Gene	8685
22101005	1116	1166	low density lipoprotein receptor related protein-2	Gene	4036
22101005	1168	1172	LRP2	Gene	4036
22101005	1176	1183	megalin	Gene	4036
22101005	1199	1204	Abeta	Gene	351
22101005	1223	1233	neprilysin	Gene	4311
22101005	1235	1238	NEP	Gene	4311
22101005	1241	1265	insulin-degrading enzyme	Gene	3416
22101005	1267	1270	IDE	Gene	3416
22101005	1297	1302	MMP-9	Gene	4318
22101005	1356	1359	NEP	Gene	4311
22101005	1361	1364	IDE	Gene	3416
22101005	1369	1375	SCARB1	Gene	949
22101005	1418	1423	MARCO	Gene	8685
22101005	1425	1429	LRP2	Gene	4036
22101005	1434	1439	MMP-9	Gene	4318
22101005	1507	1510	NEP	Gene	4311
22101005	1512	1515	IDE	Gene	3416
22101005	1520	1526	SCARB1	Gene	949
22101005	1573	1581	Abetafib	Chemical	-
22101005	1649	1652	NEP	Gene	4311
22101005	1695	1699	ApoE	Gene	348
22101005	1725	1730	Abeta	Gene	351
22101005	1754	1760	SCARB1	Gene	949
22101005	1804	1808	ApoE	Gene	348
22101005	1889	1896	SAP-C1q	Gene	712
22101005	1907	1913	SCARB1	Gene	949
22101005	2030	2032	AD	Disease	MESH:D000544
22101005	2033	2041	patients	Species	9606
22101005	2066	2071	Abeta	Gene	351
22101005	2134	2137	IDE	Gene	3416
22101005	2139	2142	NEP	Gene	4311
22101005	2146	2152	SCARB1	Gene	949
22101005	2163	2166	NEP	Gene	4311
22101005	2171	2177	SCARB1	Gene	949
22101005	2259	2264	Abeta	Gene	351
22101005	2289	2294	ApoE.	Gene	348
22101005	2376	2378	AD	Disease	MESH:D000544
22101005	2443	2445	AD	Disease	MESH:D000544
22101005	Association	3416	351
22101005	Association	351	4036
22101005	Association	351	712
22101005	Association	351	8685
22101005	Bind	351	949
22101005	Association	MESH:D000544	351
22101005	Association	351	4318
22101005	Association	351	4311
22101005	Positive_Correlation	348	949
22101005	Positive_Correlation	348	4311
22101005	Association	1191	351
22101005	Positive_Correlation	712	949
22101005	Association	348	351

